<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7026011/results/search/drug/results.xml">
  <result pre="commonly known anti-herpetic drugs that are currently being used include" exact="acyclovir" post="(ACV), penciclovir, and famciclovir, which inhibit HSV-1 and HSV-2"/>
  <result pre="low price, tolerability and safety (Hassan et al., 2015). Importantly," exact="acyclovir" post="needs to be activated intracellularly by its phosphorylation into"/>
  <result pre="acyclovir needs to be activated intracellularly by its phosphorylation into" exact="acyclovir" post="triphosphate for exerting its antiviral activity. This process is"/>
  <result pre="by the viral thymidine kinase (TK, UL23 gene), which catalyzes" exact="acyclovir" post="into acyclovir monophosphate, thus increasing the concentration of acyclovir"/>
  <result pre="viral thymidine kinase (TK, UL23 gene), which catalyzes acyclovir into" exact="acyclovir" post="monophosphate, thus increasing the concentration of acyclovir within infected"/>
  <result pre="catalyzes acyclovir into acyclovir monophosphate, thus increasing the concentration of" exact="acyclovir" post="within infected cells by reducing its exit from the"/>
  <result pre="out by cellular kinases and once in its triphosphate form," exact="acyclovir" post="becomes a substrate for the viral DNA polymerase interfering"/>
  <result pre="(TK), which decreases enzyme expression or modifies substrate specificity abrogating" exact="acyclovir" post="phosphorylation, or by acquiring mutations in the gene encoding"/>
  <result pre="et al., 1983; Leflore et al., 2000). Valacyclovir, Penciclovir, and" exact="Famciclovir" post="Besides ACV, there are other alternatives to treat skin"/>
  <result pre="topically (Emmert, 2000). To increase the bioavailability of acyclovir, an" exact="L-valine" post="ester of acyclovir was developed. Valacyclovir is a prodrug"/>
  <result pre="To increase the bioavailability of acyclovir, an L-valine ester of" exact="acyclovir" post="was developed. Valacyclovir is a prodrug of ACV with"/>
  <result pre="bioavailability of acyclovir, an L-valine ester of acyclovir was developed." exact="Valacyclovir" post="is a prodrug of ACV with enhanced absorption at"/>
  <result pre="at the intestinal level (54%) (Soul-Lawton et al., 1995). Later," exact="penciclovir" post="was developed with the aim of being phosphorylated more"/>
  <result pre="rapidly than ACV, and consequently has a higher half-life than" exact="acyclovir" post="(Hodge and Perkins, 1989). While acyclovir has a half-life"/>
  <result pre="a higher half-life than acyclovir (Hodge and Perkins, 1989). While" exact="acyclovir" post="has a half-life of 0.7 h for HSV-1 and"/>
  <result pre="of 0.7 h for HSV-1 and 1 h for HSV-2," exact="penciclovir" post="has a half-life of 10 h for HSV-1 and"/>
  <result pre="HSV-1 and 20 h for HSV-2 (Luber and Flaherty, 1996)." exact="Famciclovir" post="is a prodrug that derives into penciclovir and has"/>
  <result pre="and Flaherty, 1996). Famciclovir is a prodrug that derives into" exact="penciclovir" post="and has increased oral bioavailability (Hodge et al., 1989)."/>
  <result pre="virus infections (Chi et al., 2015; Chen et al., 2016)." exact="Valacyclovir" post="has also been approved for the treatment of HSV-1"/>
  <result pre="well as VZV and cytomegalovirus (Ormrod et al., 2000). Furthermore," exact="famciclovir" post="is approved for treating herpes viruses, such as HSV-1"/>
  <result pre="VZV (Simpson and Lyseng-Williamson, 2006). Resistance to valacyclovir, penciclovir, and" exact="famciclovir" post="can occur. Furthermore, there is cross-resistance between valacyclovir- and"/>
  <result pre="cross-resistance between valacyclovir- and acyclovir-resistant HSV isolates (Reusser, 1996), because" exact="valacyclovir" post="is derived from acyclovir (Moomaw et al., 2003). On"/>
  <result pre="acyclovir-resistant HSV isolates (Reusser, 1996), because valacyclovir is derived from" exact="acyclovir" post="(Moomaw et al., 2003). On the other hand, cross"/>
  <result pre="et al., 2003). On the other hand, cross resistance to" exact="penciclovir" post="and the prodrug famciclovir may arise in acyclovir-resistant HSV-1"/>
  <result pre="the other hand, cross resistance to penciclovir and the prodrug" exact="famciclovir" post="may arise in acyclovir-resistant HSV-1 isolates in immunocompromised patients"/>
  <result pre="1993). Some studies have reported HSV-1 and HSV-2 resistance to" exact="penciclovir" post="in cell cultures and in immunocompromised patients related to"/>
  <result pre="Sarisky et al., 2002, 2003; Bacon et al., 2003). Ganciclovir," exact="Cidofovir" post="and Foscarnet In the last decade, alternatives to ACV"/>
  <result pre="treatment have emerged and become commercially available as therapeutic drugs." exact="Ganciclovir" post="is a nucleic acid analog that does not require"/>
  <result pre="which significantly determines the frequency of administration (De Clercq, 2013)." exact="Ganciclovir" post="is indicated for the treatment of CMV, particularly for"/>
  <result pre="patients (Buhles et al., 1988; Poole and James, 2018). However," exact="ganciclovir" post="has also been reported to have antiviral activity against"/>
  <result pre="of herpes simplex virus epithelial keratitis (ClinicalTrials.gov NCT03217474). Of note," exact="ganciclovir" post="has been reported to produce considerable adverse side effects"/>
  <result pre="last decades as second-line drugs that are commercially available are" exact="cidofovir" post="(an acyclic nucleotide analog) (Ashley et al., 1988; Blot"/>
  <result pre="two compounds affect different steps in the viral replication cycle." exact="Cidofovir" post="acts as a nucleotide analog and polymerase inhibitor with"/>
  <result pre="more effective block in the replication of viral DNA than" exact="acyclovir" post="(Ho et al., 1991). Importantly, cidofovir has a phosphonate"/>
  <result pre="of viral DNA than acyclovir (Ho et al., 1991). Importantly," exact="cidofovir" post="has a phosphonate group that does not require an"/>
  <result pre="initial phosphorylation step by HSV proteins (Ho et al., 1991)." exact="Cidofovir" post="has shown to be efficacious against acyclovir-resistant isolates of"/>
  <result pre="study was carried out to evaluate the effectivity of topical" exact="cidofovir" post="for refractory mucocutaneous HSV-1 and HSV-2 in AIDS; However,"/>
  <result pre="In one case, three patients with bone marrow transplants received" exact="cidofovir" post="as a therapy, but nevertheless showed HSV-related diseases symptoms."/>
  <result pre="cidofovir as a therapy, but nevertheless showed HSV-related diseases symptoms." exact="Cidofovir" post="resistance was confirmed in one of the three cases"/>
  <result pre="of the viral DNA polymerase (Wyles et al., 2005). Notably," exact="cidofovir" post="resistance has also been reported in children, particularly in"/>
  <result pre="hematopoietic stem cell transplants that received, in a prophylactic manner" exact="acyclovir" post="and cidofovir together, because ganciclovir produced adverse effects. Unfortunately,"/>
  <result pre="cell transplants that received, in a prophylactic manner acyclovir and" exact="cidofovir" post="together, because ganciclovir produced adverse effects. Unfortunately, these children"/>
  <result pre="received, in a prophylactic manner acyclovir and cidofovir together, because" exact="ganciclovir" post="produced adverse effects. Unfortunately, these children showed HSV-related stomatitis"/>
  <result pre="produced adverse effects. Unfortunately, these children showed HSV-related stomatitis during" exact="cidofovir" post="treatment and the authors suggested that the treatment with"/>
  <result pre="cidofovir treatment and the authors suggested that the treatment with" exact="cidofovir" post="did not prevent HSV-1 reactivation in the patients (Dvorak"/>
  <result pre="HSV-1 reactivation in the patients (Dvorak et al., 2009). Nevertheless," exact="cidofovir" post="is considered a good option when encountering HSV isolates"/>
  <result pre="and foscarnet (in vitro), in which case the treatment with" exact="cidofovir" post="was effective against this drug-resistant HSV-1. Another study reporting"/>
  <result pre="foscarnet in a girl with lymphatic leukemia indicated that only" exact="cidofovir" post="treatment was successful at helping avoid recurrent oral stomatitis"/>
  <result pre="recent years. One of these alternatives is a combination of" exact="acyclovir" post="and hydrocortisone for topical use (Xerese®, Medivir). This formulation"/>
  <result pre="One of these alternatives is a combination of acyclovir and" exact="hydrocortisone" post="for topical use (Xerese®, Medivir). This formulation reduces the"/>
  <result pre="herpetic lesions by 1.6 days (compared to 1.0 days by" exact="acyclovir" post="when applied alone as a topic in that study)"/>
  <result pre="consists of an aliphatic chain (hydrophobic linear chain) with an" exact="alcohol" post="group at one of its ends and has emulsifying"/>
  <result pre="its effectiveness side by side with other compounds such as" exact="acyclovir" post="5% cream and Xerese® (Woo and Challacombe, 2007). One"/>
  <result pre="analog Approved by FDA and EMA Gnann et al., 1983" exact="Valacyclovir" post="Inhibitor of viral DNA replication Nucleoside analog Approved by"/>
  <result pre="analog Approved by FDA and EMA Schuster et al., 2016" exact="Penciclovir" post="Inhibitor of viral DNA replication Nucleoside analog Approved by"/>
  <result pre="analog Approved by FDA and EMA Meira et al., 2019" exact="Famciclovir" post="Inhibitor of viral DNA replication Nucleoside analog Approved by"/>
  <result pre="replication Nucleoside analog Approved by FDA and EMA Mondal, 2007" exact="Ganciclovir" post="Inhibitor of viral DNA replication Nucleoside analog Approved by"/>
  <result pre="replication Pyrophosphate analog Approved by FDA and EMA Crumpacker, 1992" exact="Cidofovir" post="Inhibitor of viral DNA replication Nucleotide analog Approved by"/>
  <result pre="EMA Lea and Bryson, 1996 Docosanol Viral entry inhibitor Saturated" exact="alcohol" post="Approved by FDA and EMA Treister and Woo, 2010"/>
  <result pre="Alkylamine Stand-by in the United States Taylor-Robinson and Ballard, 2001" exact="Idoxuridine" post="Inhibitor of viral DNA replication Deoxyuridine analog Approved by"/>
  <result pre="2015; De Clercq and Li, 2016; Roozbahani and Hammersmith, 2018" exact="Vidarabine" post="Inhibitor of viral DNA replication Nucleoside analog Approved by"/>
  <result pre="inhibitor Being assessed in clinical trials Wald et al., 2014" exact="Nelfinavir" post="mesylate Inhibits the maturation and export of viral particles"/>
  <result pre="Other Anti-HSV Compounds Other anti-HSV compounds, are the nucleoside analogs" exact="idoxuridine" post="and vidarabine, which are currently discontinued as there are"/>
  <result pre="a nucleoside analogs is mainly used to treat herpetic keratitis." exact="Idoxuridine" post="is a thymidine (pyrimidine) analog that was identified as"/>
  <result pre="better-tolerated and less-toxic compounds (Wilhelmus, 2015). On the other hand," exact="vidarabine" post="is a purine analog with fewer side-effects than idoxuridine,"/>
  <result pre="be efficacious against HSV-1 and at least as effective as" exact="acyclovir" post="in the treatment of HSV-1 infection (Chou and Hong,"/>
  <result pre="(Chono et al., 2010), pritelivir (Wald et al., 2014), and" exact="nelfinavir" post="mesylate (Kalu et al., 2014). Brincidofovir is an acyclic"/>
  <result pre="phase against HSV-1 and HSV-2 (Chono et al., 2010). Finally," exact="nelfinavir" post="mesylate, the mesylate salt of the antiviral drug nelfinavir"/>
  <result pre="Finally, nelfinavir mesylate, the mesylate salt of the antiviral drug" exact="nelfinavir" post="which has been characterized as a HIV-1 protease inhibitor"/>
  <result pre="of viral particles (Kalu et al., 2014). As a consequence," exact="nelfinavir" post="mesylate is currently being assessed in a clinical study"/>
  <result pre="penetration into Vero cells and had a synergistic effect with" exact="acyclovir" post="(De Sousa Cardozo et al., 2014). Interestingly, this compound"/>
  <result pre="and post-infection. Additionally, in this study a synergistic effect between" exact="acyclovir" post="and the ethanolic extracts was reported in cell cultures"/>
  <result pre="strongest antiviral activity against HSV-2, greater than that observed for" exact="acyclovir" post="(Brezáni et al., 2018). Other essential oils, particularly those"/>
  <result pre="activity against HSV-1 when combined with acyclovir, as compared to" exact="acyclovir" post="alone (Kurokawa et al., 1995). On the other hand,"/>
  <result pre="honey (Semprini et al., 2019). Here, the botanical compound and" exact="acyclovir" post="were applied topically as a cream up to five"/>
  <result pre="the medical-grade kanuka honey did not provide better efficacy than" exact="acyclovir" post="5% (Semprini et al., 2019). On the other hand,"/>
  <result pre="H.LevinM. J.LearyJ. J.SariskyR. T.SuttonD. (2003). Herpes simplex virus resistance to" exact="acyclovir" post="and penciclovir after two decades of antiviral therapy.Clin. Microbiol."/>
  <result pre="J.SariskyR. T.SuttonD. (2003). Herpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapy.Clin. Microbiol. Rev.16114–128. 10.1128/cmr.16.1.114-128.200312525428"/>
  <result pre="active compound.Microb. Pathog.114291–298. 10.1016/j.micpath.2017.12.01729223449 BlotN.SchneiderP.YoungP.JanvresseC.DehesdinD.TronP.et al. (2000). Treatment of an" exact="acyclovir" post="and foscarnet-resistant herpes simplex virus infection with cidofovir in"/>
  <result pre="of an acyclovir and foscarnet-resistant herpes simplex virus infection with" exact="cidofovir" post="in a child after an unrelated bone marrow transplant.Bone"/>
  <result pre="(2001). Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a child.Pediatr. Infect. Dis. J.201083–1086. 10.1097/00006454-200111000-0001611734717 BuckC. B.ThompsonC."/>
  <result pre="papillomavirus infection.PLoS Pathog.2:e69. 10.1371/journal.ppat.002006916839203 BuhlesW. C.MastreB. J.TinkerA. J.StrandV.KoretzS. H. (1988)." exact="Ganciclovir" post="treatment of life-or sight-threatening cytomegalovirus infection: experience in 314"/>
  <result pre="1 and 2.J. Antimicrob. Chemother.651733–1741. 10.1093/jac/dkq19820534624 ChouT. Y.HongB. Y. (2014)." exact="Ganciclovir" post="ophthalmic gel 0.15% for the treatment of acute herpetic"/>
  <result pre="(2009). Development of herpes simplex virus stomatitis during receipt of" exact="cidofovir" post="therapy.Clin. Infect. Dis.49e92–e95. 10.1086/60567819761410 EkorM. (2014). The growing use"/>
  <result pre="L. (2000). Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1%" exact="hydrocortisone" post="cream (ME-609) for treatment of UV radiation-induced herpes labialis.Antimicrob."/>
  <result pre="(1999). Treatment of mucocutaneous herpes simplex virus infections unresponsive to" exact="acyclovir" post="with topical foscarnet cream in AIDS patients: a phase"/>
  <result pre="Microbiol. Rev.29149–161. 10.1128/CMR.00043-1526561565 KaluN. N.DesaiP. J.ShirleyC. M.GibsonW.DennisP. A.AmbinderR. F. (2014)." exact="Nelfinavir" post="inhibits maturation and export of herpes simplex virus 1.J."/>
  <result pre="al. (1995). Efficacy of traditional herbal medicines in combination with" exact="acyclovir" post="against herpes simplex virus type 1 infection in vitro"/>
  <result pre="Dis.20e12977. 10.1111/tid.1297730120866 LefloreS.AndersonP. L.FletcherC. V. (2000). A risk-benefit evaluation of" exact="aciclovir" post="for the treatment and prophylaxis of herpes simplex virus"/>
  <result pre="simplex virus.Int. J. Biol. Macromol.102605–612. 10.1016/j.ijbiomac.2017.04.04328431944 LuberA. D.FlahertyJ. F. (1996)." exact="Famciclovir" post="for treatment of herpesvirus infections.Ann. Pharmacother.30978–985. 10.1177/1060028096030009138876860 MaF.ShenW.ZhangX.LiM.WangY.ZouY.et al."/>
  <result pre="cytomegalovirus infection.Drugs48455–484. 10.2165/00003495-199448030-000097527763 MarkowitzM.ConantM.HurleyA.SchlugerR.DuranM.PeterkinJ.et al. (1998). A preliminary evaluation of" exact="nelfinavir" post="mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 Protease,"/>
  <result pre="R.HartlineC. B.LanierE. R.QuenelleD. C. (2011). CMX001 potentiates the efficacy of" exact="acyclovir" post="in herpes simplex virus infections.Antimicrob. Agents Chemother.554728–4734. 10.1128/AAC.00545-1121788472 PujolC."/>
  <result pre="carotenoid sources.J. Appl. Phycol.24731–741. 10.1007/s10811-011-9692-1 SariskyR. T.BaconT.BoonR.LockeL.NguyenT. T.LearyJ.et al. (2002)." exact="Penciclovir" post="susceptibilities of herpes simplex virus isolates from patients using"/>
  <result pre="Penciclovir susceptibilities of herpes simplex virus isolates from patients using" exact="penciclovir" post="cream for treatment of recurrent herpes labialis.Antimicrob. Agents Chemother.462848–2853."/>
  <result pre="10.1128/aac.46.9.2848-2853.200212183237 SariskyR. T.BaconT. H.BoonR. J.DuffyK. E.EsserK. M.LearyJ.et al. (2003). Profiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
  <result pre="in cell culture.Pharmazie56343–347. 11338678 SchusterA. K.HarderB. C.SchlichtenbredeF. C.JarczokM. N.TesarzJ. (2016)." exact="Valacyclovir" post="versus acyclovir for the treatment of herpes zoster ophthalmicus"/>
  <result pre="culture.Pharmazie56343–347. 11338678 SchusterA. K.HarderB. C.SchlichtenbredeF. C.JarczokM. N.TesarzJ. (2016). Valacyclovir versus" exact="acyclovir" post="for the treatment of herpes zoster ophthalmicus in immunocompetent"/>
  <result pre="essential oils leaves.Biol. Res.481–5.25654588 SempriniA.SingerJ.BraithwaiteI.ShorttN.ThayabaranD.McConnellM.et al. (2019). Kanuka honey versus" exact="aciclovir" post="for the topical treatment of herpes simplex labialis: a"/>
  <result pre="protein synthesis.Planta Med.73200–205. 10.1055/s-2007-96710917285480 SpruanceS. L. (1993). Prophylactic chemotherapy with" exact="acyclovir" post="for recurrent herpes simplex labialis.J. Med. Virol.41(1 Suppl), 27–32."/>
  <result pre="mice.Science173843–845. 10.1126/science.173.3999.8434328483 StrandA.BöttigerD.GeverL. N.WheelerW. (2012). Safety and tolerability of combination" exact="acyclovir" post="5% and hydrocortisone 1% cream in adolescents with recurrent"/>
  <result pre="N.WheelerW. (2012). Safety and tolerability of combination acyclovir 5% and" exact="hydrocortisone" post="1% cream in adolescents with recurrent herpes simplex labialis.Pediatr."/>
  <result pre="Antimicrob. Chemother.46685–693. 10.1093/jac/46.5.68511062186 ThinR. N.NabarroJ. M.ParkerJ. D.FiddianA. P. (1983). Topical" exact="acyclovir" post="in the treatment of initial genital herpes.Sex Transm. Infect.59116–119."/>
 </snippets>
</snippetsTree>
